INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest

INmune Bio, Inc. (NASDAQ:INMB) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,530,000 shares, an increase of 6.3% from the March 15th total of 1,440,000 shares. Based on an average daily trading volume, of 86,500 shares, the short-interest ratio is currently 17.7 days. Currently, 13.0% of the company’s stock are short sold.

INmune Bio Stock Down 7.8 %

INmune Bio stock opened at $9.58 on Tuesday. The company’s 50 day moving average is $11.89 and its two-hundred day moving average is $10.26. The firm has a market cap of $172.73 million, a PE ratio of -5.74 and a beta of 1.99. INmune Bio has a 52-week low of $6.50 and a 52-week high of $14.74.

Institutional Trading of INmune Bio

Several hedge funds have recently modified their holdings of INMB. Tower Research Capital LLC TRC purchased a new stake in INmune Bio during the 3rd quarter worth about $25,000. Bank of America Corp DE increased its stake in shares of INmune Bio by 152.1% during the first quarter. Bank of America Corp DE now owns 4,717 shares of the company’s stock worth $30,000 after buying an additional 2,846 shares during the period. Advisor Group Holdings Inc. raised its holdings in INmune Bio by 52.9% in the fourth quarter. Advisor Group Holdings Inc. now owns 9,250 shares of the company’s stock valued at $59,000 after acquiring an additional 3,200 shares in the last quarter. LPL Financial LLC acquired a new stake in INmune Bio in the third quarter valued at approximately $68,000. Finally, Osaic Holdings Inc. lifted its stake in INmune Bio by 41.1% in the second quarter. Osaic Holdings Inc. now owns 11,200 shares of the company’s stock worth $102,000 after acquiring an additional 3,265 shares during the last quarter. 12.72% of the stock is currently owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression.